Genetic Changes In The Ebola Virus.
Genetic changes that have occurred in the Ebola virus over the mould few decades could become it more difficult for scientists to find ways to investigate the deadly pathogen, a new study says. Many of the most promising experimental drugs being developed to disturbance Ebola bind to and target a section of the virus's genetic sequence or a protein derived from that genetic sequence. If there are significant changes in Ebola's genetic sequence, these drugs may not work, the researchers explained. The researchers compared the genetic makeup of the Ebola family causing the progress outbreak in West Africa with the genetic makeup of strains that caused outbreaks in Africa in 1976 and 1995.
Compared to the older strains, the widespread heritage had changes in about 3 percent of its genetic structure, the work authors said. The findings were published Jan. 20 online in the almanac mBio. "Our work highlights the genetic changes that could affect these sequence-based drugs that were first designed in the early 2000s based on virus strains from outbreaks in 1976 and 1995," mull over senior author Gustavo Palacios said in a journal news release.
Showing posts with label ebola. Show all posts
Showing posts with label ebola. Show all posts
Saturday 29 June 2019
Saturday 8 June 2019
An Experimental Ebola Vaccine
An Experimental Ebola Vaccine.
Early results suggest an exploratory Ebola vaccine triggers an untouched response and is safe to use. However, larger clinical trials in West Africa are needed to affect if the immune response generated by the vaccine is large enough to protect against Ebola infection, said the researchers at Oxford University in the UK This vaccine innards against the Zaire damage of Ebola currently circulating in West Africa. It doesn't contain contagious Ebola virus material, so it cannot cause Ebola infection in people who receive it.
The vaccine is being developed by the US National Institutes of Health and GlaxoSmithKline. The beforehand doses of the vaccine for use in staggering clinical trials in West Africa have been delivered to Liberia. The Oxford University whirl included 60 healthy volunteers who were monitored for 28 days after receiving three unheard-of doses of the vaccine. The volunteers will continue to be monitored for six months. "The vaccine was well tolerated.
Early results suggest an exploratory Ebola vaccine triggers an untouched response and is safe to use. However, larger clinical trials in West Africa are needed to affect if the immune response generated by the vaccine is large enough to protect against Ebola infection, said the researchers at Oxford University in the UK This vaccine innards against the Zaire damage of Ebola currently circulating in West Africa. It doesn't contain contagious Ebola virus material, so it cannot cause Ebola infection in people who receive it.
The vaccine is being developed by the US National Institutes of Health and GlaxoSmithKline. The beforehand doses of the vaccine for use in staggering clinical trials in West Africa have been delivered to Liberia. The Oxford University whirl included 60 healthy volunteers who were monitored for 28 days after receiving three unheard-of doses of the vaccine. The volunteers will continue to be monitored for six months. "The vaccine was well tolerated.
Friday 24 May 2019
Ebola Epidemic Has Slowed Significantly
Ebola Epidemic Has Slowed Significantly.
West Africa's Ebola scourge has slowed significantly, but robustness officials are hesitant to say the lethal virus is no longer a threat. Ebola infections have killed more than 8600 ancestors and sickened 21000, mostly in the countries of Liberia, Sierra Leone and Guinea, since cases start with surfaced in Guinea last winter. Infections in all three countries have dropped in latest months, with Liberia experiencing the greatest falloff, the World Health Organization and others have reported in current days. Sierra Leone currently has the highest reproach of infection, with 118 people being treated for Ebola.
But, that number is less than half what it was just two weeks ago, according to a New York Times report. Only five mobile vulgus are being treated for Ebola in Liberia just now, the Associated Press reported Tuesday. That country experienced more than 300 young Ebola cases a week late last summer. But it's too betimes to predict that Liberia will soon be free of Ebola infection, Liberia's director of Ebola response, Tolbert Nyenswah, told reporters.
West Africa's Ebola scourge has slowed significantly, but robustness officials are hesitant to say the lethal virus is no longer a threat. Ebola infections have killed more than 8600 ancestors and sickened 21000, mostly in the countries of Liberia, Sierra Leone and Guinea, since cases start with surfaced in Guinea last winter. Infections in all three countries have dropped in latest months, with Liberia experiencing the greatest falloff, the World Health Organization and others have reported in current days. Sierra Leone currently has the highest reproach of infection, with 118 people being treated for Ebola.
But, that number is less than half what it was just two weeks ago, according to a New York Times report. Only five mobile vulgus are being treated for Ebola in Liberia just now, the Associated Press reported Tuesday. That country experienced more than 300 young Ebola cases a week late last summer. But it's too betimes to predict that Liberia will soon be free of Ebola infection, Liberia's director of Ebola response, Tolbert Nyenswah, told reporters.
Subscribe to:
Posts (Atom)